



GUINEA COVID-19 PREPAREDNESS AND RESPONSE PROJECT (P174032)

WESTERN AND CENTRAL AFRICA | Guinea | Health, Nutrition & Population Global Practice |
IBRD/IDA | Investment Project Financing | FY 2020 | Seq No: 6 | ARCHIVED on 21-Jun-2022 | ISR51751 |

Implementing Agencies: Ministere de la Santé, Republic of Guinea

Key Dates**Key Project Dates**

Bank Approval Date: 17-Jun-2020

Effectiveness Date: 28-Jul-2020

Planned Mid Term Review Date: 09-May-2022

Actual Mid-Term Review Date: 23-May-2022

Original Closing Date: 31-Jul-2022

Revised Closing Date: 31-Dec-2022

Project Development Objectives

Project Development Objective (from Project Appraisal Document)

To prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness in Guinea.

Has the Project Development Objective been changed since Board Approval of the Project Objective?

No

Components Table

Name

Emergency COVID-19 Response:(Cost \$37.80 M)

Project Implementation Management and Monitoring and Evaluation:(Cost \$1.30 M)

Overall Ratings

Name	Previous Rating	Current Rating
Progress towards achievement of PDO	<input type="checkbox"/> Satisfactory	<input type="checkbox"/> Satisfactory
Overall Implementation Progress (IP)	<input type="checkbox"/> Satisfactory	<input type="checkbox"/> Satisfactory
Overall Risk Rating	<input type="checkbox"/> High	<input type="checkbox"/> Substantial

Implementation Status and Key Decisions

The parent project and the Additional Financing (AF) became effective on July 28, 2020 and August 17, 2021 respectively. As of March 31, the targets for all the three Project Development Objectives (PDO) indicators included in the parent project had been surpassed. The PDO indicator "Percentage of population fully vaccinated, which is included in the priority population targets defined in the national plan" was added to the AF. As of March 31, 2022, the values of this indicator was 17.7 percent, compared to an end-target of 31.6 percent. Progress towards achievement of the PDO and overall implementation progress remain satisfactory and moderately satisfactory, respectively. The task team is preparing a second AF, which will be used to procure vaccines and support the delivery of vaccines that meet the World Bank's vaccine approval criteria.

MPA Program Development Objective



The Program Development Objective is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness

Multiphase Programmatic Approach (MPA) Status

As of June 15, 2022, 88 MPA-projects had been approved with a total commitment of US\$4.3 billion. One operation (Guatemala) was cancelled in mid-September 2021, at the request of the Government. Six parent projects have been restructured to include vaccine-related procurement. **Total disbursements as of June 15, 2022, amount to US\$3.6 billion or 84% of overall commitments.** This amount does not include disbursements under MPA-V operations which are reported together with AF-V operations. **Sixty-seven (67) country projects or 77% of projects approved have reached 70-100% disbursement** (reasons for >100% disbursements relate to fluctuations between the Euro and the SDR against the US\$). **Out of the 67 operations, 48 operations or 72% have disbursed over 90% of commitments. Of these, 30 operations are fully disbursed. There are thirteen (13) operations with closing dates by the end of FY22. Other 10 operations which had closing dates by the end of the FY have extended their closing dates. There are 12 operations with disbursements under 50%. Out of these 12 operations, one has not disbursed, and four have disbursed 30 percent or less.** The projects are benefitting around 3.7 billion people or 50% of the global population. Of the 87 active projects: (i) 33 are in Africa – 12 in AFE and 21 in AFW; (ii) 12 in East Asia; (iii) 14 in Europe and Central Asia; (iv) 11 in Latin America and the Caribbean; (v) 8 in Middle East and North Africa; and (vi) 9 in South Asia. Eighty-six (86) or 99% of projects approved are disbursing. MNA has the highest percentage of disbursements, followed by SRA, EAP, ECA and LAC, AFE and AFW. Retroactive Financing represents 26% of commitments. **Country teams for operations, which have been under implementation for twelve months or more by June 30, 2022, are preparing Mid-Term Review (MTR) ISRs to inform the Global MPA MTR, which will be prepared early next FY.**

Streamlined procedures, delegated approvals, coupled with flexible project design and intensified efforts across the Bank have contributed to the progress. Implementation is being guided by Bank teams working in parallel with other health related projects, including Additional Financing operations supporting vaccine procurement and deployment efforts. Implementation continues to face challenges as several countries are still under different levels of mobility restrictions. Bank staff are operating in a hybrid environment with some days at the office and others at home. Notwithstanding the challenges, the MPA is on track to achieve its PrDO, which is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness. The significant level of disbursements attests to the strong implementation of the Bank' response thanks to the commitment of counterparts supported by Bank country teams.

The Additional Financing (MPA AF-V) to the COVID-19 Strategic Preparedness and Response Program utilizing the Multiphase Programmatic Approach ("Global COVID-19 MPA") was approved by the Board on October 13, 2021. The AF-V is significantly expanding Bank support to client countries for COVID-19 vaccination, with the aim to support vaccination of 1 billion people globally. The AF-V was approved with an envelope of US\$12 billion (\$6 billion from IDA and \$6 billion from IBRD) in financing. **On June 30, 2021, President Malpass announced the expansion of financing available for COVID-19 vaccine financing to \$20 billion over the next 18 months, adding \$8 billion to the previously announced \$12 billion.** This financing is critical to expand affordable and equitable financing for vaccine purchase and deployment. The AF-V is expected to enable vaccination for up to 750 million people, with potential surge capacity for an additional 250 million people in the poorest countries (depending on the delivered price of approved vaccines) while scaling support to strengthen immunization delivery, with design flexibility at the country level. The AF-V is a scale-up of planned vaccination activities anticipated and supported under the Global COVID-19 MPA and a key contribution to the WBG's overall COVID-19 response.



As of June 15, 2022, the Bank has approved 105 operations (including MPA-V operations) to support vaccine procurement and rollout in 77 countries amounting to \$9.6 billion. The 105 operations approved, include 6 operations that involved restructuring of parent projects (Bhutan, Cameroon, North Macedonia, Philippines, and Pakistan) and in the case of Lebanon, restructuring of the Health Resilience Project. Of the 105 approved operations: (i) 56 are in Africa – 26 in AFE and 30 in AFW; (ii) 9 in East Asia and the Pacific; (iii) 11 in Europe and Central Asia; (iv) 11 in Latin America and the Caribbean; (v) 9 in Middle East and North Africa; and (vi) 9 in South Asia. Fifty-three (53) projects are disbursing. **Total disbursements as of June 15, 2022, under these projects amount to US\$3.4 billion or 35% of overall commitments. Disbursements under MPA-V operations are included in this total while disbursements under the six restructured projects are counted under parent projects. Sixteen (16) operations have disbursed over 70% of their commitments. Out of the 16, seven have disbursed 90%. Retroactive Financing represents 44% of overall commitments.** Thirteen (13) new operations are under various stages of processing. As with the MPA operations, streamlined procedures, delegated approval, coupled with flexible project design, and intensified efforts across the Bank have contributed to the rapid design and processing of the operations. Eighty-eight (88) loan/financing agreements have been signed. Also, eighty-six (86) loan/financing agreements have become effective; several others are expected to become effective in the coming weeks. Implementation of the AF-V operations, as with MPA operations is facing challenges as several countries are still under different levels of mobility restrictions and counterparts and Bank teams are operating in a hybrid environment with some days at the office and some at home. Countries are dealing with new waves of infections, as the Omicron variant continues to spread rapidly among populations.

Risks

Systematic Operations Risk-rating Tool

Risk Category	Rating at Approval	Previous Rating	Current Rating
Political and Governance	<input type="checkbox"/> Substantial	<input type="checkbox"/> High	<input type="checkbox"/> High
Macroeconomic	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial
Sector Strategies and Policies	<input type="checkbox"/> Moderate	<input type="checkbox"/> Moderate	<input type="checkbox"/> Moderate
Technical Design of Project or Program	<input type="checkbox"/> Moderate	<input type="checkbox"/> Moderate	<input type="checkbox"/> Moderate
Institutional Capacity for Implementation and Sustainability	<input type="checkbox"/> Moderate	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial
Fiduciary	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial
Environment and Social	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial
Stakeholders	<input type="checkbox"/> Moderate	<input type="checkbox"/> High	<input type="checkbox"/> Substantial
Other	<input type="checkbox"/> Moderate	<input type="checkbox"/> Moderate	<input type="checkbox"/> Moderate
Overall	<input type="checkbox"/> Substantial	<input type="checkbox"/> High	<input type="checkbox"/> Substantial

Results

PDO Indicators by Objectives / Outcomes

To prevent, detect and respond to COVID-19 and strengthen national systems for public health emergen



▶ Suspected cases of COVID-19 cases reported and investigated based on national guidelines (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	400.00	22,593.00	22,593.00	1,000.00
Date	28-Jul-2020	31-Mar-2022	31-Mar-2022	31-Jul-2022
▶ Designated laboratories with COVID-19 diagnostic equipment, test kits, and reagents (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	4.00	12.00	12.00	8.00
Date	28-Jul-2020	31-Mar-2022	31-Mar-2022	31-Jul-2022
▶ Acute healthcare facilities with isolation capacity (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	7.90	100.00	100.00	90.00
Date	28-Jul-2020	31-Mar-2022	31-Mar-2022	31-Jul-2022
Comments:	Acute facilities are related to epidemiological treatment centers. There are 38 epidemiological treatment centers			
▶ Population fully vaccinated, which is included in the priority population targets defined in the national plan, by gender (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	17.70	17.70	31.60
Date	16-Apr-2021	31-Mar-2022	31-Mar-2022	31-Jul-2022
□ Women fully vaccinated, which is included in the priority population targets defined in the national plan (Percentage, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	44.00	50.00
Date	16-Apr-2021	31-Aug-2021	31-Mar-2022	31-Jul-2022

Overall Comments

Three Project Development Objectives (PDO) indicators were included in the parent project:

1. Number of suspected cases of COVID-19 reported and investigated based on national guidelines;
2. Number of designated laboratories with COVID-19 diagnostic equipment, test kits, and reagents; and
3. Percentage of acute healthcare facilities with isolation capacity.



As of March 31, 2022, the target for all three indicators had been surpassed.

The PDO indicator “Percentage of population fully vaccinated, which is included in the priority population targets defined in the national plan, and its sub-indicator “Percentage of women fully vaccinated among the total population fully vaccinated” were added to the Additional Financing (AF). As of March 31, 2022, the values of this indicator and its sub-indicator were 17.7 percent (compared to an end-target of 31.6 percent) and 44 percent (compared to an end-target of 50 percent), respectively.

Intermediate Results Indicators by Components

Emergency COVID-19 Response				
► Health staff trained in infection prevention and control per MOH-approved protocols (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	1,154.00	1,154.00	1,000.00
Date	28-Jul-2020	31-Mar-2022	31-Mar-2022	31-Jul-2022
► Designated laboratories with staff trained to conduct COVID-19 diagnosis (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	4.00	12.00	12.00	8.00
Date	28-Jul-2020	31-Mar-2022	31-Mar-2022	31-Jul-2022
► Country has prepared guidelines to care for COVID-19 patients (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	28-Jul-2020	31-Mar-2022	31-Mar-2022	31-Jul-2022
► Start-ups recruited for the development of innovative and digital technology solution for accelerated COVID-19 prevention and response (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	4.00	4.00	5.00
Date	28-Jul-2020	31-Mar-2022	31-Mar-2022	31-Jul-2022
► Grievances addressed within the time specified in the project implementation manual (Percentage, Custom)				



	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	85.00	0.00	80.00
Date	28-Jul-2020	31-Mar-2022	31-Mar-2022	30-Dec-2022
Comments:	This is a Citizen Engagement beneficiary feedback indicator. It will help track the project beneficiary feedback during the project implementation			
► Key gender-responsive messages and materials developed for public communications and advocacy, in alignment with demand plan (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	16-Apr-2021	31-Mar-2022	31-Mar-2022	31-Jul-2022
► Cold rooms fully equipped (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	2.00
Date	16-Apr-2021	31-Mar-2022	31-Mar-2022	31-Jul-2022
► Eight (8) health regions with an AEFI monitoring committee (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	100.00	100.00
Date	16-Apr-2021	31-Mar-2022	31-Mar-2022	31-Jul-2022
► Beneficiaries reporting that community engagement and outreach meet their needs (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	50.00
Date	16-Apr-2021	31-Mar-2022	31-Mar-2022	30-Dec-2022

Implementation Management and Monitoring and Evaluation

► M&E system established to monitor COVID-19 preparedness and response plan (Yes/No, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	28-Jul-2020	31-Mar-2022	31-Mar-2022	31-Jul-2022



▶ Vaccination sites that transmit their data via DHIS2 (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	100.00	100.00
Date	16-Apr-2021	31-Mar-2022	31-Mar-2022	31-Jul-2022
▶ HMIS collecting sex and age disaggregated data on COVID-19 indicators for testing, treatment, and vaccines (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	16-Apr-2021	31-Mar-2022	31-Mar-2022	31-Jul-2022
▶ Vaccinators trained on GBV/SEA/SH (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	95.00
Date	16-Apr-2021	31-Mar-2022	31-Mar-2022	30-Dec-2022

Overall Comments

Six intermediate indicators were included in the parent project, with July 31, 2022 as the end target date:

1. Number of health staff trained in infection prevention and control per MOH-approved protocols;
2. Number of designated laboratories with staff trained to conduct COVID-19 diagnosis;
3. Country has prepared guidelines to care for COVID-19 patients;
4. Number of start-ups recruited for the development of innovative and digital technological solutions for COVID-19 prevention and response;
5. Percentage of grievance addressed within the time specified in the project implementation manual; and
6. M&E system established to monitor COVID-19 preparedness and response plan.

As of March 31, 2022, the target for four indicators had either been attained or surpassed. These indicators are (1) Number of health staff trained in infection prevention and control per MOH-approved protocols; (2) Number of designated laboratories with staff trained to conduct COVID-19 diagnosis; (3) Country has prepared guidelines to care for COVID-19 patients; and (4) M&E system established to monitor COVID-19 preparedness and response plan. Regarding the number of start-ups recruited for the development of innovative and digital technology solutions for COVID-19 prevention and response, four out of five start-ups have been recruited. Lastly, the MTR mission enabled the task team to clarify the meaning of the indicator "Grievances addressed within the time specified in the project implementation manual" with the PIU. The task team realized that this indicator had not been monitored. Therefore, its value has been reduced to 0. PIU has started monitoring this indicator as of the MTR mission. Since this indicator was included as part of the World Bank's corporate commitment to citizen engagement, it will continue to be used until the closing date of the AF.



Seven intermediate indicators were included in the AF:

1. Key gender-responsive messages and materials developed for public communications and advocacy, in alignment with demand plan;
2. Number of cold rooms fully equipped;
3. Percentage of all eight (8) health regions with an AEFI monitoring committee;
4. Percentage of beneficiaries reporting that community engagement and outreach meet their needs;
5. Percentage of vaccination sites that transmit their data via DHIS2;
6. HMIS collecting sex and age disaggregated data on COVID-19 indicators for testing, treatment, and vaccines; and
7. Percentage of vaccinators trained on GBV/SEA/SH

As of March 31, 2022, the target for four indicators had been attained. These are (1) Key gender-responsive messages and materials developed for public communications and advocacy, in alignment with demand plan; (2) Percentage of all eight (8) health regions with an AEFI monitoring committee; (3) Percentage of vaccination sites that transmit their data via DHIS2; and (4) HMIS collecting sex and age disaggregated data on COVID-19 indicators for testing, treatment, and vaccines. Activities related to the other three indicators are on track.

Performance-Based Conditions

Data on Financial Performance


Disbursements (by loan)

Project	Loan/Credit/TF	Status	Currency	Original	Revised	Cancelled	Disbursed	Undisbursed	% Disbursed
P174032	IDA-67350	Effective	USD	5.45	5.45	0.00	5.31	0.43	93%
P174032	IDA-69700	Effective	USD	14.10	14.10	0.00	0.00	13.91	0%
P174032	IDA-D6870	Effective	USD	5.45	5.45	0.00	5.74	0.00	100%
P174032	IDA-D8940	Effective	USD	14.10	14.10	0.00	10.77	2.66	80%

Key Dates (by loan)

Project	Loan/Credit/TF	Status	Approval Date	Signing Date	Effectiveness Date	Orig. Closing Date	Rev. Closing Date
P174032	IDA-67350	Effective	17-Jun-2020	25-Jun-2020	28-Jul-2020	31-Jul-2022	31-Jul-2022
P174032	IDA-69700	Effective	29-Jun-2021	01-Jul-2021	17-Aug-2021	31-Dec-2022	31-Dec-2022
P174032	IDA-D6870	Effective	17-Jun-2020	25-Jun-2020	28-Jul-2020	31-Jul-2022	31-Jul-2022
P174032	IDA-D8940	Effective	29-Jun-2021	01-Jul-2021	17-Aug-2021	31-Dec-2022	31-Dec-2022

Cumulative Disbursements



Restructuring History

There has been no restructuring to date.

Related Project(s)

P176706-Additional Financing for COVID-19 Emergency Response and System Preparedness Strengthening Project ,P178602-Second Additional Financing to Guinea COVID-19 Emergency Response and System Preparedness Strengthening Project